Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of ...
. *Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics.
Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...
Basel, October 26, 2025 – Novartis today announced that it has entered into an agreement to acquire Avidity Biosciences, Inc. (Nasdaq: RNA), a San Diego-based, biopharmaceutical company focused on a ...
About Novartis Immunology At Novartis, we’re advancing bold science for autoimmune diseases, where meaningful therapeutic progress has long stalled. With a growing legacy of first-in-class innovation ...
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo ...
If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in Europe Scemblix ...
Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-controlled ...
EAST HANOVER, N.J., Sept. 30, 2025 -- Novartis announced today that Rhapsido ® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with ...
ノバルティス ファーマ株式会社（本社：東京都港区、代表取締役社長：ジョンポール・プリシーノ）（以下「ノバルティス ファーマ」）は、本日、「プルヴィクト ® 静注」（一般名 ...
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease Pacibekitug is a promising ...
About Novartis in Cardiovascular Disease At Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We’re proud ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback